Massively parallel AST

BacterOMIC provides fastest access to complete information to direct targeted antibiotic therapies.

BacterOmic delivers complete information on phenotypic antibiotic susceptibility of bacterial pathogens: MIC values for all antibiotics and synergies between up to 20 combinations. It enables precision therapies already after the first test.

BacterOMIC provides MIC values for 2.5-10 times more agents than competitors, eliminating the need of additional testing, reducing cost and time.

Technology:
  • Antimicrobial stewardship
  • Microbial diagnostics

Microorganisms:
  • Bacteria

Application:
  • Human
  • Veterinary

Development stage:
  • Development

Organization:
  • Company

Partnering:
  • Co-develop, Joint Venture, Sell

We seek strategic partnership with a global diagnostic systems supplier that can best leverage the market value of Bacteromic, offering complete AST information for targeted antibiotics therapies, within established workflow and test-price structure.

BacterOmic is a med-tech startup developing automated AST to provide doctors MIC values for all clinically relevant antibiotics from a single test

BacterOmic is part of Scope Fluidics Group, that develops also point-of-care molecular Dx system – PCR|ONE featuring 15-minute time-to-result and high multiplexing capacity. The first PCR|ONE panel detects and characterizes MRSA infections.


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!